RNXT
Price:
$1.285
Market Cap:
$47.00M
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
Industry
Biotechnology
IPO Date
2021-08-26
Stock Exchange
NASDAQ
Ticker
RNXT
According to RenovoRx, Inc.’s latest financial reports and current stock price. The company's current ROE is -119.58%. This represents a change of 233.63% compared to the average of -35.84% of the last 4 quarters.
The mean historical ROE of RenovoRx, Inc. over the last ten years is 0.66%. The current -119.58% ROE has changed -18296.63% with respect to the historical average. Over the past ten years (40 quarters), RNXT's ROE was at its highest in in the December 2023 quarter at 107.57%. The ROE was at its lowest in in the September 2023 quarter at -23683.33%.
Average
0.66%
Median
-8.16%
Minimum
-196.83%
Maximum
341.07%
Discovering the peaks and valleys of RenovoRx, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 242.94%
Maximum Annual ROE = 341.07%
Minimum Annual Increase = -315.13%
Minimum Annual ROE = -196.83%
Year | ROE | Change |
---|---|---|
2024 | -196.83% | -157.71% |
2023 | 341.07% | -315.13% |
2022 | -158.54% | 242.94% |
2021 | -46.23% | -254.52% |
2020 | 29.92% | -13.43% |
The current ROE of RenovoRx, Inc. (RNXT) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-4.77%
5-year avg
-6.12%
10-year avg
0.66%
RenovoRx, Inc.’s ROE is greater than ABVC BioPharma, Inc. (-31.13%), greater than Indaptus Therapeutics, Inc. (-333.04%), less than Pasithea Therapeutics Corp. (-0.42%), greater than Better Therapeutics, Inc. (-221.99%), greater than Forte Biosciences, Inc. (-149.15%), less than Virpax Pharmaceuticals, Inc. (692.20%), greater than TransCode Therapeutics, Inc. (-470.15%),
Company | ROE | Market cap |
---|---|---|
-31.13% | $67.42M | |
-333.04% | $6.87M | |
-0.42% | $5.13M | |
-221.99% | $5.45K | |
-149.15% | $69.45M | |
692.20% | $439.85K | |
-470.15% | $7.24M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like RenovoRx, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like RenovoRx, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is RenovoRx, Inc.'s ROE?
How is the ROE calculated for RenovoRx, Inc. (RNXT)?
What is the highest ROE for RenovoRx, Inc. (RNXT)?
What is the 3-year average ROE for RenovoRx, Inc. (RNXT)?
What is the 5-year average ROE for RenovoRx, Inc. (RNXT)?
How does the current ROE for RenovoRx, Inc. (RNXT) compare to its historical average?